UCLA Hematology Oncology - Santa Monica

Summary

UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Solid Tumors, Cancer and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 104 conditions. There are 8 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.

Top PIs

Clinical Trials running at UCLA Hematology Oncology - Santa Monica

Lung Cancer

Esophageal Cancer

Pancreatic Cancer

Cancer

Breast Cancer

Prostate Cancer

Bladder Cancer

Solid Tumors

Non-Small Cell Lung Cancer

Colorectal Cancer

MK-2870

for Non-Small Cell Lung Cancer

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.

Recruiting

2 awards

Phase 3

9 criteria

Nivolumab + Relatlimab vs Pembrolizumab with Chemotherapy

for Lung Cancer

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Recruiting

2 awards

Phase 3

3 criteria

CoREST Inhibitor + Anti-PD-1 Therapy

for Solid Cancers

This trial is testing a new drug, TNG260, combined with an existing cancer treatment, pembrolizumab, in patients with advanced solid tumors that have an STK11 mutation. TNG260 aims to block proteins that help cancer grow, while pembrolizumab boosts the immune system to fight the cancer. Pembrolizumab has been shown to be an effective and safe therapeutic option for various advanced cancers, including endometrial cancer and melanoma. The study will determine the best dose, safety, and effectiveness of this combination.

Recruiting

1 award

Phase 1 & 2